Back

Mumps

General information

    • Surveillance period: 1985 - active
    • Temporal resolution: Annual surveillance
    • Publication frequency: Data are updated every year when our yearly report is published
  • Case definition :
    A case that meets one of the following:
    * Unilateral or bilateral parotidian tumefaction, aching, recent, isolated or associated with a testicular, pancreatic, meningeal, or encephalic impairment.
    * In the absence of parotitis: association of orchitis, meningitis or pancreatitis and mumps seroconversion.
  • Description for each case: age; sex; contagion during the 21 days preceding the illness and if so in what environment (nursery, daycare, nanny, school, medical office, consulting or other); serological confirmation (presence of IgM or IgG rate increased by a factor of 4 at least); complications and if so which ones; vaccination status and if vaccination number of vaccine dose(s), date of vaccination and source of information.

To view or download Sentinelles data, click on the button below

Data access

All publications associated with this disease
  • Prévot-Monsacré P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, Souty C, Mamou T, Hamel J, Antona D, Mathieu P, Vasseur P, Lévy-Bruhl D, Baroux N, Rossignol L, Vaillant L, Guerrisi C, Hanslik T, Dina J, Blanchon T. What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020. Vaccine. 2023. PubMed 10.1016/j.vaccine.2023.12.017
  • Coffinières E, Turbelin C, Riblier D, Aouba A, Levy-Bruhl D, Arena C, Chiappe SG, Ferry JP, Hanslik T, Blanchon T. Mumps: burden of disease in France. Vaccine. 2012. 30(49):7013-8 PubMed HAL 10.1016/j.vaccine.2012.09.070